Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT07424118
REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription (REMIDEP-HTA)
Efficacy of the REMIDEP-HTA Program in Hypertension Remission and Pharmacological Deprescription: A Multicenter Randomized Clinical Trial
Sponsor: Evelyn Vanina Re
Conditions
Essential Hypertension
Interventions
Intensive Lifestyle Intervention Pharmacological Deprescribing Algorithm Standard Medical Care
Updated 1 time since 2026 Last updated: Feb 13, 2026 Started: Apr 30, 2026 Primary completion: Nov 30, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This NA trial investigates Essential Hypertension and is currently actively recruiting participants. Evelyn Vanina Re leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Evelyn Vanina Re
Data source: Universidad Abierta Interamericana
For direct contact, visit the study record on ClinicalTrials.gov .